Patents Examined by Maury Audet
  • Use of chelating agent and peptide antimicrobial compounds
    Patent number: 10265376
    Abstract: The inventors provide the use of a chelating agent and an antimicrobial agent that is effective against a plant pathogenic microorganism to inhibit the growth of and/or kill a plant pathogenic microorganism on a plant; the use of a chelating agent to increase the activity of an antimicrobial that is effective against a plant pathogenic microorganism; a method of inhibiting the growth of and/or killing a plant pathogenic microorganism comprising administering to a plant in need thereof a chelating agent and an antimicrobial agent that is effective against a plant pathogenic microorganism; and a method of increasing the activity of an antimicrobial that is effective against a plant pathogenic microorganism comprising using said antimicrobial with a chelating agent.
    Type: Grant
    Filed: October 12, 2011
    Date of Patent: April 23, 2019
    Assignee: Consumo Em Verde Biotecnologia Das Plantas, S.A.
    Inventors: Alexandra Manuela Lourenço Carreira, Ricardo Manuel De Seixas Boavida Ferreira, Sara Alexandra Valadas Da Silva Monteiro
  • Method for separating proteins from animal or human plasma, or plants, using a pH gradient method
    Patent number: 10266561
    Abstract: The present subject matter is directed to a method for separating proteins of plasma using pH adjustment including the steps of reconstituting Fraction III, Fraction IV, or plasma paste, in water for injection; adjusting pH value to 1 and temperature from 1° C. to 30° C.; centrifuging the resulting suspension at 6,000 rpm at 2-8° C. for 20 min; collecting the resulting paste 1 (P1) and supernatant 1 (S1); reconstituting P1 in WFI and adjust the pH to 2; and repeating step 3) to step 5) until the pH of supernatant reaches 14. According to the method, a new formulation of immunoglobulin is prepared from plasma Fraction III and Fraction IV.
    Type: Grant
    Filed: September 28, 2016
    Date of Patent: April 23, 2019
    Inventor: Kieu Hoang
  • Chimeric antigen receptors to control HIV infection
    Patent number: 10246505
    Abstract: The present disclosure is directed to novel multispecific chimeric antigen receptor (CAR) proteins and DNA sequences encoding these proteins. The CARs comprise at least two extracellular domains fused, via a transmembrane domain to a cytoplasmic signaling domain comprising two signaling domains. The disclosure further relates to nucleic acids encoding the novel CARs, to host cells expressing the novel CARs, and to methods of using the CARs to co-stimulate effector functions in the cells and for using cells expressing the receptors for treatment of disease and viral infections. The disclosure also relates to methods of generating a recombinant T cell with reduced susceptibility to HIV infection.
    Type: Grant
    Filed: November 25, 2014
    Date of Patent: April 2, 2019
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Edward A. Berger, Mustafa H. Ghanem, Barna Dey
  • Peptide containing conjugates for dual molecular delivery of oligonucleotides
    Patent number: 10239957
    Abstract: Disclosed herein is a peptide containing conjugate comprising (P)c-(L)d-(G)e, wherein P is a peptide and each occurance of P is independently selected from Table 2; L is an optional linker and each occurance of L, if present, is independently selected from Table 3; G is a targeting ligand and each occurance of G is independently selected from Table 4; d is 0, 1, 2, 3, 4, 5 or 6; and each of c and e is independently 1, 2, 3, 4, 5 or 6. The conjugate can be administered to a subject either alone or in combination with a composition comprising R-(L)a-(G)b, wherein R is an oligonucleotide as defined herein, to inhibit expression of a gene of the subject.
    Type: Grant
    Filed: November 3, 2014
    Date of Patent: March 26, 2019
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Steven L. Colletti, Thomas J. Tucker, David M. Tellers, Boyoung Kim, Rob Burke, Kathleen B. Calati, Matthew G. Stanton, Rubina G. Parmar, Jeffery G. Aaronson, Weimin Wang
  • Dermaseptin-type and piscidin-type antimicrobial peptides
    Patent number: 10221222
    Abstract: Antimicrobial agents, including antimicrobial peptides (AMPs) and uses thereof. Compositions and methods of using dermaseptin-type and piscidin-type antimicrobial peptides that demonstrate activity and improved therapeutic indices against microbial pathogens. The peptide compositions demonstrate the ability to not only maintain or improve antimicrobial activity against bacterial pathogens including Gram-negative microorganisms Acinetobacter baumannii and Pseudomonas aeruginosa, but also significantly decrease hemolytic activity against human red blood cells. Specificity determinants within the AMPS change selectivity from broad spectrum antimicrobial activity to AMPS with gram-negative selectivity.
    Type: Grant
    Filed: January 26, 2015
    Date of Patent: March 5, 2019
    Assignee: The Regents of the University of Colorado, a body corporate
    Inventors: Ziqing Jiang, Robert S. Hodges, Lajos Gera, Colin T. Mant
  • Peptide for preventing or treating inflammatory diseases and use thereof
    Patent number: 10213475
    Abstract: The present invention relates to a peptide for preventing or treating inflammatory diseases and a use thereof. According to the novel dimeric peptide according to the present invention, it is possible to not only exhibit an excellent therapeutic effect through anti-inflammatory action but also have a very small-sized peptide, thereby minimizing side effects due to the administration of external substances and will be expected to be used as an active substance that can replace existing therapeutic agents for inflammatory diseases.
    Type: Grant
    Filed: February 27, 2017
    Date of Patent: February 26, 2019
    Assignee: BIO PEP CO., LTD.
    Inventors: Dae Ho Cho, Kyung Eun Kim, Sun Young Park, Youn Kyung Houh
  • Functionalized titanium binding peptides and implants coated with same
    Patent number: 10213527
    Abstract: An isolated peptide is disclosed. The peptide comprises a titanium oxide binding amino acid sequence connected to a heterologous biologically active amino acid sequence via a beta sheet breaker linker, wherein: (i) the titanium oxide binding amino acid sequence is selected to bind coordinatively with titanium oxide; (ii) the titanium oxide binding amino acid sequence is selected to induce a beta sheet structure; and (ii) the titanium oxide binding amino acid sequence binds to titanium oxide with a higher affinity than said biologically active amino acid sequence binds to the titanium oxide under physiological conditions. Use of the peptides and titanium devices comprising same are also disclosed.
    Type: Grant
    Filed: August 3, 2017
    Date of Patent: February 26, 2019
    Assignee: Ben-Gurion University of the Negev Research and Development Authority
    Inventors: Hanna Rapaport, Anna Gittelman
  • Nasal powder formulation for treatment of hypoglycemia
    Patent number: 10213487
    Abstract: The present invention provides a powder formulation containing glucagon or a glucagon analog for nasal administration, useful in the treatment of hypoglycemia, and in particular the treatment of severe hypoglycemia. The present invention also provides a method of making this powder formulation, and to devices and methods for using the powder formulation.
    Type: Grant
    Filed: February 16, 2016
    Date of Patent: February 26, 2019
    Assignee: Eli Lilly and Company
    Inventors: Sankaram Mantripragada, Claude A. Piche, Jo Jan Filip Van Betsbrugge
  • Modified kappa light chain-binding polypeptides
    Patent number: 10208091
    Abstract: A kappa light chain-binding polypeptide comprising or consisting essentially of one or more binding domains of Peptostreptococcus Protein L, each of said domains being selected from the group consisting of domain 2, domain 3 and domain 4.
    Type: Grant
    Filed: December 11, 2015
    Date of Patent: February 19, 2019
    Assignee: GE HEALTHCARE BIOPROCESS R&D AB
    Inventors: Gustav Rodrigo, Mats Ander, Tomas Bjorkman
  • Modified kappa light chain-binding polypeptides
    Patent number: 10208092
    Abstract: The invention discloses kappa light chain-binding polypeptide comprising a mutated binding domain of Peptostreptococcus protein L, wherein at least one asparagine residue of a parental domain defined by, or having at least 95% or 98% sequence homology with, SEQ ID NO: 2-6 or 2 has been mutated to another amino acid residue which is not asparagine, proline or cysteine.
    Type: Grant
    Filed: December 11, 2015
    Date of Patent: February 19, 2019
    Assignee: GE Healthcare Bio-Process R&D AB
    Inventors: Gustav Rodrigo, Mats Ander, Tomas Bjorkman
  • Antimicrobial compositions and method of use thereof
    Patent number: 10206974
    Abstract: The present application discloses a method for treating microbial infection using an antimicrobial composition comprises antimicrobial peptide which contains at least one VGFPV motif.
    Type: Grant
    Filed: January 3, 2017
    Date of Patent: February 19, 2019
    Assignee: MOREHOUSE SCHOOL OF MEDICINE
    Inventors: Vincent Craig Bond, Michael Powell, Ming Bo Huang, Syed Ali, Martin Neville Shelton
  • Peptide for preventing or treating inflammatory diseases and use thereof
    Patent number: 10206969
    Abstract: The present invention relates to a peptide for preventing or treating inflammatory diseases and a use thereof. According to the novel dimeric or trimeric peptide according to the present invention, it is possible to not only exhibit an excellent therapeutic effect through anti-inflammatory action but also have a very small-sized peptide, thereby minimizing side effects due to the administration of external substances. Therefore, it is expected that the peptide can be used as an active substance that can replace existing therapeutic agents for inflammatory diseases.
    Type: Grant
    Filed: February 27, 2017
    Date of Patent: February 19, 2019
    Assignee: BIO PEP CO., LTD.
    Inventors: Dae Ho Cho, Kyung Eun Kim, Sun Young Park, Myung Jin Jung, Joo Hyun Lee
  • Peptide for skin regeneration or wound treatment and use thereof
    Patent number: 10188694
    Abstract: The present invention relates to a peptide for skin regeneration or wound healing and a use thereof. The novel peptide according to the present invention not only promotes the wound healing by increasing the production amount of collagen in dermal fibroblasts but also has an excellent whitening effect by inhibiting the production amount of melanin and tyrosinase activity of melanoma cells, and consists of peptides having a very small size to minimize side effects according to administration of external substances of very small peptides. As a result, it is expected that the novel peptide can be used as an active substance that can replace existing skin regeneration or would therapeutic agents.
    Type: Grant
    Filed: March 21, 2017
    Date of Patent: January 29, 2019
    Assignee: BIO PEP CO., LTD.
    Inventors: Dae Ho Cho, Min Chan Gil, So Mi Lee, Myun Soo Kim
  • Insulin receptor partial agonists
    Patent number: 10183981
    Abstract: Insulin dimers and insulin analog dimers that act as partial agonists at the insulin receptor are disclosed.
    Type: Grant
    Filed: June 13, 2018
    Date of Patent: January 22, 2019
    Inventors: Songnian Lin, Lin Yan, Pei Huo, Dmitri Pissarnitski, Danqing Feng, Ravi Nargund, Yuping Zhu, Ahmet Kekec, Christina B. Madsen-Duggan, Zhi-Cai Shi, Zhicai Wu, Yingjun Mu
  • Methods of cell culture
    Patent number: 10144944
    Abstract: Polypeptide preparations having target levels of glycans, and methods of producing such polypeptide preparations using putrescine, are described.
    Type: Grant
    Filed: April 25, 2017
    Date of Patent: December 4, 2018
    Assignee: Momenta Pharmaceuticals, Inc.
    Inventor: Holly Prentice
  • Neutral nanotransporters
    Patent number: 10138485
    Abstract: Neutral lipid formulations for nucleic acid delivery are provided according to the invention. The neutral lipid formulations include hydrophobically modified polynucleotides and fat mixtures. Methods of using the neutral lipid formulations are also provided.
    Type: Grant
    Filed: September 22, 2009
    Date of Patent: November 27, 2018
    Assignee: RXi Pharmaceuticals Corporation
    Inventors: Anastasia Khvorova, William Salomon, Joanne Kamens, Dmitry Samarsky, Tod M. Woolf, Michelle Miller, Karen G. Bulock
  • Antimicrobial peptide and uses thereof
    Patent number: 10130677
    Abstract: The invention relates to antimicrobial peptides, pharmaceutical compositions comprising the peptides and to uses thereof for in the treatment or prevention of microbial, bacterial, fungal, viral and parasitic infection.
    Type: Grant
    Filed: December 12, 2014
    Date of Patent: November 20, 2018
    Assignees: Academisch Ziekenhuis Leiden h.o.d.n. LUMC, Academisch Medisch Centrum
    Inventors: Petrus Hendricus Nibbering, Anna de Breij, Robert Alexander Cordfunke, Sebastianus Antonius Johannes Zaat, Jan Wouter Drijfhout
  • Mutated immunoglobulin-binding polypeptides
    Patent number: 10112980
    Abstract: The invention discloses a polypeptide with improved alkaline stability, which polypeptide comprises a mutant of a B or C domain of Staphylococcus Protein A (SpA), as specified by SEQ ID NO 1 or SEQ ID NO 2, or of Protein Z, as specified by SEQ ID NO 3, wherein at least the glutamic acid residue at position 15 has been mutated to an amino acid other than asparagine. The invention also discloses multimers of said polypeptide, as well as separation matrices comprising the multimers or polypeptides.
    Type: Grant
    Filed: May 18, 2017
    Date of Patent: October 30, 2018
    Assignee: GE HEALTHCARE BIOPROCESS R&D AB
    Inventors: Mats Ander, Goran Bauren, Tomas Bjorkman, Gustav Rodrigo
  • Protein SLURP-1 for use in the treatment of ocular diseases
    Patent number: 10098925
    Abstract: The present invention relates to a protein comprising SEQ ID NO:1 (mature form of SLURP-1) and to a composition comprising the same for use in inducing or accelerating cicatrization, and/or in preventing infection in the eye of a subject.
    Type: Grant
    Filed: December 9, 2013
    Date of Patent: October 16, 2018
    Assignee: Brightpulse Holding Ltd.
    Inventors: Jean-Marc Combette, Catherine Deloche, Claire Abadie, Sebastien Mouz, Julien Perino
  • Self-assembly of therapeutic agent-peptide nanostructures
    Patent number: 10098967
    Abstract: Disclosed are conjugates of hydrophobic drugs linked to protected or unprotected amino acids or peptides. The disclosed conjugates are amphiphilic and can self assemble into nantubes. Nanotubes comprising the conjugates are also described and can have high loading of the drug and protect it from degradation or elimination. The nanotubes are well suited to deliver hydrophobic and unstable drugs to individuals.
    Type: Grant
    Filed: December 3, 2013
    Date of Patent: October 16, 2018
    Assignees: Ohio State Innovation Foundation, Trustees of Boston University
    Inventors: Jonathan R. Parquette, Se Hye Kim, Mark W. Grinstaff, Jonah A. Kaplan